Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form
- PMID: 20877571
- PMCID: PMC2943925
- DOI: 10.1371/journal.pone.0012872
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form
Abstract
Botulinum neurotoxins (BoNT) are the most potent of all toxins. The 50 kDa N-terminal endopeptidase catalytic light chain (LC) of BoNT is located next to its central, putative translocation domain. After binding to the peripheral neurons, the central domain of BoNT helps the LC translocate into cytosol where its proteolytic action on SNARE (soluble NSF attachment protein receptor) proteins blocks exocytosis of acetyl choline leading to muscle paralysis and eventual death. The translocation domain also contains 105 Å -long stretch of ∼100 residues, known as "belt," that crosses over and wraps around the LC to shield the active site from solvent. It is not known if the LC gets dissociated from the rest of the molecule in the cytosol before catalysis. To investigate the structural identity of the protease, we prepared four variants of type A BoNT (BoNT/A) LC, and compared their catalytic parameters with those of BoNT/A whole toxin. The four variants were LC + translocation domain, a trypsin-nicked LC + translocation domain, LC + belt, and a free LC. Our results showed that K(m) for a 17-residue SNAP-25 (synaptosomal associated protein of 25 kDa) peptide for these constructs was not very different, but the turnover number (k(cat)) for the free LC was 6-100-fold higher than those of its four variants. Moreover, none of the four variants of the LC was prone to autocatalysis. Our results clearly demonstrated that in vitro, the LC minus the rest of the molecule is the most catalytically active form. The results may have implication as to the identity of the active, toxic moiety of BoNT/A in vivo.
Conflict of interest statement
Figures








Similar articles
-
Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.Protein J. 2008 Apr;27(3):151-62. doi: 10.1007/s10930-007-9118-8. Protein J. 2008. PMID: 18213512
-
Catalytic properties of botulinum neurotoxin subtypes A3 and A4.Biochemistry. 2009 Mar 24;48(11):2522-8. doi: 10.1021/bi801686b. Biochemistry. 2009. PMID: 19256469 Free PMC article.
-
High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.Protein J. 2017 Dec;36(6):489-501. doi: 10.1007/s10930-017-9744-8. Protein J. 2017. PMID: 29030733 Free PMC article.
-
Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function.Toxicon. 2013 Dec 1;75:101-7. doi: 10.1016/j.toxicon.2013.01.007. Epub 2013 Feb 5. Toxicon. 2013. PMID: 23396042 Free PMC article. Review.
-
Light Chain Diversity among the Botulinum Neurotoxins.Toxins (Basel). 2018 Jul 2;10(7):268. doi: 10.3390/toxins10070268. Toxins (Basel). 2018. PMID: 30004421 Free PMC article. Review.
Cited by
-
Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium.Int J Biochem Mol Biol. 2012;3(3):313-21. Epub 2012 Sep 25. Int J Biochem Mol Biol. 2012. PMID: 23097747 Free PMC article.
-
Expression and purification of recombinant TAT-BoNT/A(1-448) under denaturing and native conditions.Bioengineered. 2016 Nov;7(6):478-483. doi: 10.1080/21655979.2016.1201252. Epub 2016 Aug 26. Bioengineered. 2016. PMID: 27566060 Free PMC article.
-
Detection of botulinum neurotoxin A (BoNT/A) enzymatic activity by pregnancy test strips based on hCG-modified magnetic nanoparticles.Mikrochim Acta. 2024 Jan 29;191(2):114. doi: 10.1007/s00604-024-06197-4. Mikrochim Acta. 2024. PMID: 38286853
-
Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.J Biol Chem. 2011 Jan 21;286(3):1802-11. doi: 10.1074/jbc.M110.146464. Epub 2010 Oct 20. J Biol Chem. 2011. PMID: 20961849 Free PMC article.
-
Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication.Molecules. 2010 Dec 30;16(1):202-20. doi: 10.3390/molecules16010202. Molecules. 2010. PMID: 21193845 Free PMC article. Review.
References
-
- Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167–193. - PubMed
-
- Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys. 1995;28:423–472. - PubMed
-
- Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898–902. - PubMed
-
- Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 2000;7:693–699. - PubMed
-
- Ahmed SA, Olson MA, Ludivico ML, Gilsdorf J, Smith LA. Identification of Residues Surrounding the Active Site of Type A Botulinum Neurotoxin Important for Substrate Recognition and Catalytic Activity. Protein J. 2008;27:151–162. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous